CRISPR Therapeutics Stock News

These companies may represent the future, but their stocks are getting pummeled in the present.

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $131.10, marking a +0.41% move from the previous day.

It's a firm maybe.

Gene editing has the potential to revolutionize medicine. With CRISPR Therapeutics leading the way, CRSP stock should benefit.

CRISPR Therapeutics AG's (CRSP) CEO Samarth Kulkarni Presents At 33rd Annual ROTH Conference (Transcript)

Tesla's great, but these Cathie Wood favorites have even better growth prospects.

With possibly the worst of the novel coronavirus pandemic over, on the surface CRSP stock seems to be a worthwhile rebound pick. However, the technical outlook suggests otherwise.

ZUG, Switzerland and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for se

Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players. The post Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and ED

Crispr Therapeutics AG's (CRSP) CEO Samarth Kulkarni Presents at Barclays Global Healthcare Conference 2017 (Transcript)

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $114.65, marking a -0.73% move from the previous day.

Yields are on the rise and valuation-propelled tech is getting deflated.

With the trading day about halfway over, the broad markets had managed to push higher on the day, despite dipping into the red earlier.

The companies with game-changing technology are often the best growth picks.